Immunovant, Inc. cash flow to debt ratio of -565.71K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Immunovant, Inc.'s free cash flow has decreased 8.15% from $-376.63M last year to $-407.32M, signaling decreasing performance

Immunovant, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Immunovant, Inc.'s debt has decreased relative to shareholder equity from 0.00 last year to 0.00 today, signaling strengthened financials

Immunovant, Inc. has a net cash position, so leverage is healthy.

Immunovant, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Immunovant, Inc. has insufficient data to evaluate this check.

Immunovant, Inc.'s short-term assets of $948.82M exceed its short-term liabilities of $104.42M

Immunovant, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Immunovant, Inc.'s return on equity of -69.59%, is lower than 15.00%, indicating bad performance

Immunovant, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Immunovant, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Immunovant, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Immunovant, Inc. has negative free cash flow, indicating cash burn

Immunovant, Inc.'s yearly earnings has decreased 22.17% since last year from $-413.84M to $-505.61M, signaling decreasing performance

Immunovant, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -75.90% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Immunovant, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Immunovant, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Immunovant, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Immunovant, Inc. has insufficient data to evaluate this check.

Immunovant, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Immunovant, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Immunovant, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Immunovant, Inc. has insufficient data to evaluate this check.

Immunovant, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Immunovant, Inc. has a price-to-book ratio of 11.15x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Immunovant, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue